Acesso livre
Acesso livre

Infectologia

Covid-19: dados iniciais mostram que coriza, dor de cabeça e fadiga são os sintomas mais comuns da infecção pela variante Ômicron.

17 Dez, 2021 | 12:24h

Covid-19: Runny nose, headache, and fatigue are commonest symptoms of omicron, early data show – The BMJ

Ver também: Omicron and cold-like symptoms rapidly taking over in London – ZOE COVID Study

 

Comentário no Twitter

 

Estudo sugere que infecções em indivíduos previamente vacinados geram uma “superimunidade” à COVID-19.

17 Dez, 2021 | 12:22h

Comunicado de imprensa: Breakthrough infections generate ‘super immunity’ to COVID-19, study suggests – Oregon Health & Science University

Estudo original: Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection – JAMA

Conselheiros do CDC recomendam o uso preferencial de vacinas mRNA contra COVID em vez da vacina da J&J.

17 Dez, 2021 | 12:20h

CDC advisors recommend mRNA COVID vaccines over J&J – CIDRAP

Opinião | Estratégias de vacinação contra COVID-19 devem focar na doença grave e na equidade global.

17 Dez, 2021 | 12:19h

COVID-19 vaccine strategies must focus on severe disease and global equity – The Lancet

Como as vacinas contra COVID moldaram 2021, em 8 gráficos.

17 Dez, 2021 | 12:17h

How COVID vaccines shaped 2021 in eight powerful charts – Nature

Diretriz | Prevenção, diagnóstico e tratamento da mediastinite pós-cirúrgica em adultos.

17 Dez, 2021 | 12:11h

Prevention, Diagnosis and Management of Post-Surgical Mediastinitis in Adults Consensus Guidelines of the Spanish Society of Cardiovascular Infections (SEICAV), the Spanish Society of Thoracic and Cardiovascular Surgery (SECTCV) and the Biomedical Research Centre Network for Respiratory Diseases (CIBERES) – Journal of Clinical Medicine

Retrospectiva: principais artigos de 2021 sobre doenças infecciosas além da COVID.

17 Dez, 2021 | 12:06h

Year In Review: Top Non-COVID Infectious Diseases Articles Of 2021 – IDStewardship

 

Comentário no Twitter

 

Modelagem da mortalidade por COVID-19 em 44 países: uso de máscaras pode reduzir as mortes.

16 Dez, 2021 | 13:08h

Modeling COVID-19 Mortality Across 44 Countries: Face Covering May Reduce Deaths – American Journal of Preventive Medicine

Comentário: Mask laws could prevent unnecessary COVID-19 deaths, study shows – News Medical

Revisão revela que as diretrizes sobre Covid são baseadas em evidências fracas.

16 Dez, 2021 | 13:05h

Review uncovers weak COVID clinical practice guidelines – CIDRAP

Estudo original: Adherence of Clinical Practice Guidelines for Pharmacologic Treatments of Hospitalized Patients With COVID-19 to Trustworthy Standards: A Systematic Review – JAMA Network Open

 

Comentário no Twitter

 

Medicamento da Merck contra COVID perde seu brilho: o que isso significa para a pandemia – “Molnupiravir foi inicialmente anunciado pelos oficiais de saúde pública como um elemento que mudaria o cenário da COVID-19, mas dados finais dos estudos clínicos mostraram eficácia abaixo das expectativas.”

16 Dez, 2021 | 13:04h

Merck’s COVID pill loses its lustre: what that means for the pandemic – Nature

Conteúdos relacionados:

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID.

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.